The Paradox of Daclizumab
Phase 3 results show that daclizumab reduces disease activity in relapsing-remitting multiple sclerosis by half compared with interferon, as measured by brain imaging, with skin and other side effects. The drug works in surprising ways that are revealing new details about the pathogenesis of MS.
Phase 3 results show that daclizumab reduces disease activity in relapsing-remitting multiple sclerosis by half compared with interferon, as measured by brain imaging, with skin and other side effects. The drug works in surprising ways that are revealing new details about the pathogenesis of MS.
Three might be the lucky number for daclizumab, an investigational drug for relapsing-remitting multiple sclerosis with...
Clinical Research, Drug Development, Laboratory Research, Meetings